Cytomegalovirus Cell-mediated Immunity Assays in Pediatric Transplantation-Reference-Cited by-同舟云学术

Cytomegalovirus Cell-mediated Immunity Assays in Pediatric Transplantation

Published:2024-02-01 Issue:Supplement_1 Volume:13 Page:S22-S30
ISSN:2048-7207
Container-title:Journal of the Pediatric Infectious Diseases Society
language:en
Short-container-title:

Author:

Otto William R¹²^ORCID,Vora Surabhi B³⁴,Dulek Daniel E⁵⁶

Affiliation:

1. Division of Infectious Diseases, Cincinnati Children’s Hospital Medical Center , Cincinnati, Ohio , USA

2. Department of Pediatrics, University of Cincinnati , Cincinnati, Ohio , USA

3. Division of Infectious Diseases, Seattle Children’s Hospital , Seattle, Washington , USA

4. Department of Pediatrics, University of Washington , Seattle, Washington , USA

5. Division of Pediatric Infectious Diseases, Monroe Carell Jr Children’s Hospital at Vanderbilt , Nashville, Tennessee , USA

6. Department of Pediatrics, Vanderbilt University Medical Center , Nashville, Tennessee , USA

Abstract

Abstract Cytomegalovirus (CMV) is a significant cause of morbidity and mortality in pediatric transplantation. However, currently utilized CMV prevention paradigms have limitations, leading to research aimed at novel strategies for mitigation of CMV infection. Cell-mediated immunity (CMI) is crucial in controlling CMV infection and the use of CMV-specific CMI assays to guide prevention and treatment of CMV infection in both solid organ transplant and hematopoietic cell transplant recipients shows great promise. In this article, we review the immune response to CMV infection to highlight the rationale for CMI assays, describe available commercial assays and strategies for their use, and summarize relevant literature regarding the use of CMI assays in transplant recipients.

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/jpids/article-pdf/13/Supplement_1/S22/56778800/piae005.pdf

Reference82 articles.

1. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation;Kotton;Transplantation,2018

2. Cytomegalovirus in the transplant setting: where are we now and what happens next? A report from the international CMV symposium 2021;Kotton;Transpl Infect Dis,2022

3. Improving our mechanistic understanding of the indirect effects of CMV infection in transplant recipients;L’Huillier;Am J Transplant,2019

4. The “indirect” effects of cytomegalovirus infection;Freeman;Am J Transplant,2009

5. Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation;Chen;Blood Adv,2018